GlassScriptPhysician profile
Leah M Cecil
NPI 1417187014
$6,539.47
in general payments reported to CMS, 2019-2025
43 companies · $1,025 in 2025
The $1,025 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,192 · 2020: $537 · 2021: $1,033 · 2022: $830 · 2023: $851 · 2024: $1,071 · 2025: $1,025.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,947.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,946.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,163.95 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Sanofi US Services INC. | $964.65 | 2019 | |
| Lilly USA, LLC | $818.64 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Pfizer INC. | $558.04 | 2019-2025 | |
| Glaxosmithkline, LLC. | $325.68 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Currax Pharmaceuticals LLC | $254.43 | 2020-2025 | Contrave, Nexletol, Nexlizet |
| Bayer Healthcare Pharmaceuticals INC. | $241.38 | 2022-2025 | |
| Nestle Healthcare Nutrition INC. | $224.31 | 2020-2022 | |
| Idorsia Pharmaceuticals US INC | $192.83 | 2023-2024 | Quviviq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $172.58 | 2020-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $155.88 | 2021-2024 | Jardiance |
| Exact Sciences Corporation | $150.60 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbvie INC. | $145.25 | 2023-2025 | Ubrelvy, Qulipta |
| Merck Sharp & Dohme LLC | $112.88 | 2019-2025 | Gardasil 9, Capvaxive |
| Astrazeneca Pharmaceuticals LP | $92.55 | 2024-2025 | Airsupra |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $89.48 | 2023-2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $82.66 | 2023-2025 | Veozah |
| Amgen INC. | $62.75 | 2019-2025 | Repatha, Otezla, Repatha |
| Dexcom, INC. | $61.04 | 2024 | Dexcom G6 Transmitter |
| Teva Pharmaceuticals USA, INC. | $60.31 | 2019-2021 | |
| Adlon Therapeutics L.P. | $55.46 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $51.50 | 2022 | |
| Organon LLC | $47.75 | 2021-2025 | Nexplanon |
| Phathom Pharmaceuticals, INC. | $44.40 | 2025 | Voquezna |
| Supernus Pharmaceuticals, INC. | $39.80 | 2025 | Qelbree |
| Indivior INC. | $36.80 | 2020 | |
| Sanofi Pasteur INC. | $35.14 | 2021-2023 | |
| Coopersurgical, INC. | $32.46 | 2024 | Paragard T 380a |
| Orexo US, INC. | $27.42 | 2020-2022 | |
| Boston Scientific Corporation | $25.54 | 2025 | Wavewriter Alpha Prime 16 |
| Amneal Pharmaceuticals LLC | $21.27 | 2025 | Unithroid |
| Phadia US INC. | $19.96 | 2021 | |
| Pulmonx Corporation | $19.69 | 2024 | Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter |
| Jazz Pharmaceuticals INC. | $17.82 | 2021 | |
| Ibsa Pharma INC. | $17.74 | 2025 | Tirosint, Flector, Licart |
| Biohaven Pharmaceuticals, INC. | $16.60 | 2021 | |
| Axsome Therapeutics, INC. | $16.26 | 2025 | Sunosi |
| Otsuka America Pharmaceutical, INC. | $16.10 | 2025 | Rexulti |
| Seqirus USA INC | $15.85 | 2025 | Fluad, Flucelvax |
| Ars Pharmaceuticals Operations, INC. | $13.95 | 2025 | Neffy |
| Eisai INC. | $13.44 | 2021 | |
| Galderma Laboratories, L.P. | $12.60 | 2022 | |
| Kaleo, INC. | $12.03 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leah Cecil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.